![]() | |
Combination of | |
---|---|
Emtricitabine | Nucleoside reverse transcriptase inhibitor |
Tenofovir disoproxil | Nucleotide analogue reverse transcriptase inhibitor |
Clinical data | |
Trade names | Truvada, others |
Other names | Emtricitabine/tenofovir disoproxil fumarate |
AHFS/Drugs.com | Monograph |
MedlinePlus | a612036 |
License data | |
Pregnancy category |
|
Routes of administration | By mouth |
ATC code | |
Legal status | |
Legal status | |
Identifiers | |
CAS Number | |
PubChem CID | |
KEGG | |
NIAID ChemDB | |
(verify) |
Emtricitabine/tenofovir, sold under the brand name Truvada among others, is a fixed-dose combination antiretroviral medication used to treat and prevent HIV/AIDS.[5][6] It contains the antiretroviral medications emtricitabine and tenofovir disoproxil.[7] For treatment, it must be used in combination with other antiretroviral medications.[7][8] For prevention before exposure, in those who are at high risk, it is recommended along with safer sex practices.[7] It does not cure HIV/AIDS.[5] Emtricitabine/tenofovir is taken by mouth.[7]
Common side effects include headache, tiredness, trouble sleeping, abdominal pain, weight loss, and rash.[5] Serious side effects may include high blood lactate levels and enlargement of the liver.[7] Use of this medication during pregnancy does not appear to harm the fetus, but this has not been well studied.[1]
Emtricitabine/tenofovir was approved for medical use in the United States in 2004.[5] It is on the World Health Organization's List of Essential Medicines.[9] In the United States, emtricitabine/tenofovir was under patent by Gilead until 2020, but is now available as a generic worldwide.[10] In 2020, it was the 278th most commonly prescribed medication in the United States, with more than 1 million prescriptions.[11][12]
Truvada FDA label
was invoked but never defined (see the help page).